Literature DB >> 21074423

4-deoxy-4-fluoro-xyloside derivatives as inhibitors of glycosaminoglycan biosynthesis.

Yasuhiro Tsuzuki1, Thao Kim Nu Nguyen, Dinesh R Garud, Balagurunathan Kuberan, Mamoru Koketsu.   

Abstract

Various 4-deoxy-4-fluoro-xylosides were prepared using click chemistry for evaluating their potential utility as inhibitors of glycosaminoglycan biosynthesis. 2,3-Di-O-benzoyl-4-deoxy-4-fluoro-β-D-xylopyranosylazide, obtained from L-arabinopyranose by six steps, was treated with a wide variety of azide-reactive triple bond-containing hydrophobic agents in the presence of Cu(2+) salt/ascorbic acid, a step known as click chemistry. After click chemistry, benzoylated derivatives were deprotected under Zemplén conditions to obtain 4-deoxy-4-fluoro-xyloside derivatives. A mixture of α:β-isomers of twelve derivatives were then separated on a reverse phase C18 column using HPLC and the resulting twenty four 4-deoxy-4-fluoro-xylosides were evaluated for their ability to inhibit glycosaminoglycan biosynthesis in endothelial cells. We identified two xyloside derivatives that selectively inhibit heparan sulfate and chondroitin sulfate/derman sulfate biosynthesis without affecting cell viability. These novel derivatives can potentially be used to define the biological actions of proteoglycans in model organisms and also as therapeutic agents to combat various human diseases in which glycosaminoglycans participate.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21074423     DOI: 10.1016/j.bmcl.2010.10.085

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Novel glycosaminoglycan biosynthetic inhibitors affect tumor-associated angiogenesis.

Authors:  Karthik Raman; Masayuki Ninomiya; Thao Kim Nu Nguyen; Yasuhiro Tsuzuki; Mamoru Koketsu; Balagurunathan Kuberan
Journal:  Biochem Biophys Res Commun       Date:  2010-11-19       Impact factor: 3.575

Review 2.  The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

Authors:  Vishnu C Ramani; Anurag Purushothaman; Mark D Stewart; Camilla A Thompson; Israel Vlodavsky; Jessie L-S Au; Ralph D Sanderson
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

3.  Probing the acceptor active site organization of the human recombinant β1,4-galactosyltransferase 7 and design of xyloside-based inhibitors.

Authors:  Mineem Saliba; Nick Ramalanjaona; Sandrine Gulberti; Isabelle Bertin-Jung; Aline Thomas; Samir Dahbi; Chrystel Lopin-Bon; Jean-Claude Jacquinet; Christelle Breton; Mohamed Ouzzine; Sylvie Fournel-Gigleux
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

4.  A visualizable chain-terminating inhibitor of glycosaminoglycan biosynthesis in developing zebrafish.

Authors:  Brendan J Beahm; Karen W Dehnert; Nicolas L Derr; Joachim Kuhn; Johann K Eberhart; Dorothe Spillmann; Sharon L Amacher; Carolyn R Bertozzi
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-19       Impact factor: 15.336

5.  Selective Inhibition of Heparan Sulphate and Not Chondroitin Sulphate Biosynthesis by a Small, Soluble Competitive Inhibitor.

Authors:  Marissa L Maciej-Hulme; Eamon Dubaissi; Chun Shao; Joseph Zaia; Enrique Amaya; Sabine L Flitsch; Catherine L R Merry
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 6.208

Review 6.  The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance.

Authors:  Sen Guo; XinYi Wu; Ting Lei; Rui Zhong; YiRan Wang; Liang Zhang; QingYi Zhao; Yan Huang; Yin Shi; Luyi Wu
Journal:  Front Cell Dev Biol       Date:  2022-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.